title: Gamma Knife radiosurgery of primary and metastatic malignant brain tumors, a preliminary report.
abstract: Between February 1993 and March 1994, 75 metastases, 16 gliomas and 2 AIDS-related malignant lymphomas were treated with Gamma Knife radiosurgery. Metastatic brain tumors (54% lung cancer, 14% breast cancer, 13.5% melanoma) were the most frequent and clinically rewarding cases. So-called local control was achieved in almost all patients, the vast majority showing neurological improvement associated with radiological disappearance or dramatic shrinkage of the tumor within 9-12 weeks from treatment. According to our modified 'Pittsburgh' protocol, we have treated up to four distinct intracranial lesions, up to a total maximum volume of 20 cm3, with an average surface dose of 25 Gy, with or without additional whole brain radiotherapy (WBR). Preliminary follow-up data seem to confirm increased quality of life and survival rates. The results were particularly striking whenever primary tumors were under control, and were poorly influenced by associated WBR. Gamma Knife treatment was also performed in a selected group of patients with small-to-medium-sized, well-defined, histologically proven, cerebral gliomas. The main indications for radiosurgery were high-risk surgery, multifocal disease, ventricular seeding and unresected or recurrent tumor. The prescription doses ranged from 18 to 30 Gy, with a mean of 27 Gy. Low-grade astrocytomas (9/16 cases) showed the better clinical and radiological response to treatment, with neurological recovery and significant reduction in tumor volume within 3-5 months in 5 of the 9 patients. In 4 of 7 high-grade gliomas, there was little or no response. However, an impressive radiological regression with full clinical recovery was observed in 2 high-grade cases with small tumor volumes: a recurrent, anaplastic 'mixed glioma' of the pineal region and a double ventricular seeding of a previously operated anaplastic astrocytoma.
authors.affiliation: Department of Neurosurgery, University Hospital, Verona, Italy.
authors.forename: M A
authors.initials: MA
authors.lastname: Gerosa
authors.forename: A
authors.initials: A
authors.lastname: Nicolato
authors.forename: S
authors.initials: S
authors.lastname: Berlucchi
authors.forename: E
authors.initials: E
authors.lastname: Piovan
authors.forename: P G
authors.initials: PG
authors.lastname: Zampieri
authors.forename: A
authors.initials: A
authors.lastname: Pasoli
authors.forename: R
authors.initials: R
authors.lastname: Foroni
authors.forename: M G
authors.initials: MG
authors.lastname: Giri
authors.forename: G
authors.initials: G
authors.lastname: Marchini
authors.forename: S
authors.initials: S
authors.lastname: Babighian
mesh_terms: D001932:Brain Neoplasms / Q000556:secondary / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D005910:Glioma / Q000601:surgery*; D006801:Humans; D016483:Lymphoma, AIDS-Related / Q000601:surgery*; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D016634:Radiosurgery; D012189:Retrospective Studies; D016896:Treatment Outcome